Dr. Portia Lin, a Ph. D chemist graduated from HK Polytechnic University Department of Applied Biology and Chemical Technology, has been acting as pharmaceutical executive with 25 years of technical service, regulatory affairs, business development, marketing, portfolio and project management and commercial management experience working with both global new drug development and generic pharmaceutical companies in CDMO and generic API/DP industry.

Before joining EirGenix, Dr. Lin held senior executive level position at ScinoPharm Taiwan Ltd. – as Vice President of Sales & Marketing and Chief Strategic Officer and – as General Manager at SciAnda Shanghai Biochemical Technology, Ltd. During 1999-2024.  She started as a lead scientist and project manager in R&D and then transferred to Sales & Marketing department to be in charge of corporate business development, global strategic business planning including set-up of subsidiary/affiliate in Shanghai and Tokyo and regulatory & technical services with more than 900 DMFs in more than 100 countries for over 300 customers worldwide.  In business development, Dr. Lin completed more than 10 licensing/collaboration deals on injectable drug products including one 505b2 project for royalty and profit share incomes.

A proven track record of organization and business strategy development was established by Dr. Lin to drive revenue growth and expand customer base worldwide.  In EirGenix, Dr. Portia Lin acts as chief business officer to lead the business development for biologic CDMO and partnership/alliance management for in-house biosimilar projects.